Brofaromine

Source: Wikipedia, the free encyclopedia.
Brofaromine
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding98%
Elimination half-life9-14 hours
Identifiers
  • 4-(7-bromo-5-methoxybenzofuran-2-yl)piperidine
JSmol)
  • Brc3cc(OC)cc1c3oc(c1)C2CCNCC2
  • InChI=1S/C14H16BrNO2/c1-17-11-6-10-7-13(9-2-4-16-5-3-9)18-14(10)12(15)8-11/h6-9,16H,2-5H2,1H3 checkY
  • Key:WZXHSWVDAYOFPE-UHFFFAOYSA-N checkY
  (verify)

Brofaromine (proposed brand name Consonar) is a

depression and anxiety but its development was dropped before it was brought to market.[2]

Brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like certain of the tricyclic antidepressants.

Pharmacology

Brofaromine is a

cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia
.

See also

References

  1. ^ US Patent 4210655
  2. PMID 10063483. Free full text


Stub icon

This article about an anxiolytic is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Brofaromine&oldid=1211099329"